LMTK2 (Lemur Tyrosine Kinase 2)

News alerts, weekly reports and conference planners

6ms

The IRE1α/XBP1-mediated upregulation of LMTK2 attenuates endoplasmic reticulum stress by enhancing autophagic activity. (PubMed, Cancer Lett)

Our study reveals that ER stressors thapsigargin (Tg) and tunicamycin (Tm) upregulate LMTK2 expression via IRE1α-XBP1s signaling in colon cancer cells...Analyses of clinical colon cancer specimens indicate that LMTK2 expression levels correlate with tumor grades and poor patients' survival. These results provide compelling evidence that LMTK2 functions as an ER stress-responsive protein that maintains ER homeostasis and promotes cell survival via autophagy-dependent mechanisms.

6 months ago

Journal

TYK2 (Tyrosine Kinase 2) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • XBP1 (X-box-binding protein 1) • LMTK2 (Lemur Tyrosine Kinase 2)

9ms

VADEr: Vision Transformer-Inspired Framework for Polygenic Risk Reveals Underlying Genetic Heterogeneity in Prostate Cancer. (PubMed, medRxiv)

DARTH scores also revealed germline predispositions for particular PCa molecular subtypes, including an association between the LMTK2 locus and the SPOP subtype, both implicated in the regulation of androgen receptor activity. Overall, by effectively capturing dependencies among genetic variants and providing interpretable insights, VADEr and DARTH scores offer a promising direction for advancing genotype-to-phenotype prediction, particularly in complex disease.

9 months ago

Journal

SPOP (Speckle Type BTB/POZ Protein) • HOXB13 (Homeobox B13) • LMTK2 (Lemur Tyrosine Kinase 2)

over1year

Multifocal Papillary Thyroid Carcinomas With Discordant Molecular Drivers: Emphasizing the Morphology and Collision Tumors. (PubMed, Am J Surg Pathol)

Almost half of the cases had nodal metastasis and a third of them showed simultaneous involvement by tumors with discordant molecular drivers. The results highlight the clinical importance of identifying such cases, given the potentially different treatments.

over 1 year ago

Journal • Discordant

BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR1 (Fibroblast growth factor receptor 1) • CCDC6 (Coiled-Coil Domain Containing 6) • ETV6 (ETS Variant Transcription Factor 6) • RAS (Rat Sarcoma Virus) • NCOA4 (Nuclear Receptor Coactivator 4) • AGK (Acylglycerol Kinase) • LMTK2 (Lemur Tyrosine Kinase 2)

2years

Multifocal Papillary Thyroid Carcinomas with Discordant Molecular Drivers: A Series of Ten Cases with Emphasis on the Morphology and the Clinical Implications (USCAP 2024)

A subset (10.3%) of multifocal PTCs had discordant molecular drivers and 90.0% of them were a combination of BRAF-positive and kinase gene fusion-associated PTCs, mostly with different histologic subtypes. Half of the cases had nodal metastasis and 40% (2/5) of them showed simultaneous involvement by tumors with discordant molecular drivers. These findings highlight the clinical importance of identifying such cases given the potentially different management with specific targeted therapies.

2 years ago

Clinical • Discordant

BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR1 (Fibroblast growth factor receptor 1) • CCDC6 (Coiled-Coil Domain Containing 6) • ETV6 (ETS Variant Transcription Factor 6) • RAS (Rat Sarcoma Virus) • NCOA4 (Nuclear Receptor Coactivator 4) • LMTK2 (Lemur Tyrosine Kinase 2)

BRAF V600E • BRAF V600 • RAS mutation • NRAS Q61 • NRAS Q61R • BRAF positive

FusionPlex® Pan Solid Tumor v2 panel

2years

Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways. (PubMed, Prostate)

NGRn BPH contained significant germline alteration interactions (BRCA2_rs11571831 and TP53_rs1042522) and increased somatic alteration frequencies (LMTK2, LRP1, COL18A1, CABP1, and FKBP1C) that impact apoptosis. Normal prostate development is maintained by balancing apoptotic and proliferative activity. Dysfunction in either mechanism can lead to abnormal prostate growth. This work is the first to examine genomic sequencing in NGRn BPH and provides data that fill known gaps in the understanding BPH and how it impacts men of African ancestry.

2 years ago

Journal • BRCA Biomarker

TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • LRP1B (LDL Receptor Related Protein 1B) • PMS2 (PMS1 protein homolog 2) • BARD1 (BRCA1 Associated RING Domain 1) • HSD3B1 (Hydroxy-Delta-5-Steroid Dehydrogenase 3 Beta- And Steroid Delta-Isomerase 1) • LRP1 (LDL Receptor Related Protein 1) • PKD1 (Polycystin 1) • CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A) • DNAH9 (Dynein Axonemal Heavy Chain 9) • LMTK2 (Lemur Tyrosine Kinase 2) • PKHD1 (PKHD1 Ciliary IPT Domain Containing Fibrocystin/Polyductin) • PRKD1 (Protein Kinase D1)

2years

Molecular Findings on Plasma Cell-Free DNA Analysis Among Adults with Histiocytic Neoplasms (ASH 2023)

"cfDNA analysis may have a role to identify potential drivers of pathogenesis among cases that are unable to successfully undergo tissue molecular analysis. Further studies are underway to characterize other novel alterations that were discovered in the cfDNA analysis."

2 years ago

Clinical

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • NOTCH1 (Notch 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • MSH6 (MutS homolog 6) • NOTCH3 (Notch Receptor 3) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • FUS (FUS RNA Binding Protein) • MUTYH (MutY homolog) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TMEM127 (Transmembrane Protein 127) • LMTK2 (Lemur Tyrosine Kinase 2)

BRAF V600E • BRAF fusion • NOTCH3 mutation

over2years

Lemur tyrosine kinase 2 has a tumor-inhibition function in human glioblastoma by regulating the RUNX3/Notch pathway. (PubMed, Biochim Biophys Acta Mol Cell Res)

Moreover, the restoration of LMTK2 augmented the sensitivity of GBM cells to the chemotherapy drug temozolomide...This work indicates the deregulation of the LMTK2-mediated RUNX3/Notch signaling pathway may be a novel molecular mechanism for the malignant transformation of GBMs. This work highlights the interest in LMTK2-related approaches for treating GBM.

over 2 years ago

Journal

TCF3 (Transcription Factor 3) • TYK2 (Tyrosine Kinase 2) • RUNX3 (RUNX Family Transcription Factor 3) • LMTK2 (Lemur Tyrosine Kinase 2)

temozolomide

almost3years

Lemur tyrosine kinase 3 serves as a predictor of patient outcome and a target for the treatment of ovarian cancer (AACR 2023)

Moreover, we observed this killing as synergistic with both Cisplatin and Taxotere treatment in vitro. Thus, with dose optimization in ongoing experiments, we could expect a higher efficacy. In conclusion, this study highlighted the importance of LMTK3 as a predictor of patient clinical outcome and potential target for treatment in ovarian cancer.

almost 3 years ago

Clinical

LMTK2 (Lemur Tyrosine Kinase 2)

cisplatin • docetaxel